Cochrane Abstracts
Asenapine versus placebo for schizophrenia
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Asenapine Versus Placebo for Schizophrenia." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/439191/all/Asenapine_versus_placebo_for_schizophrenia.
Asenapine versus placebo for schizophrenia. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439191/all/Asenapine_versus_placebo_for_schizophrenia. Accessed January 27, 2025.
Asenapine versus placebo for schizophrenia. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439191/all/Asenapine_versus_placebo_for_schizophrenia
Asenapine Versus Placebo for Schizophrenia [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 January 27]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/439191/all/Asenapine_versus_placebo_for_schizophrenia.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Asenapine versus placebo for schizophrenia
ID - 439191
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/439191/all/Asenapine_versus_placebo_for_schizophrenia
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
